undefined undefined
NaN.000
NaN.00%
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
05-10 02:59
U.S. stocks traded higher toward the end of trading, with the Dow Jones index j...
05-10 02:30
BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and raises the price target from $3.25 to $3.59.
05-09 22:54
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.
05-09 22:08
Gainers: Embecta (EMBC) +40%. Zai Lab ADR (ZLAB) +25%. Warby Parker (WRBY) +17%. Notable Labs (NTBL) +13%. Personalis (PSNL) +11%. Losers: Tivic Health Systems (TIVC) -59%. CytomX Therapeutics (CTMX) ...
05-09 22:00
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-09 21:07
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market ...
05-09 20:13
Gainers Zai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursd...
05-09 20:06
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.06) by 383.33 percent. The company reported quarterly sales of $41.463 million which beat
05-09 05:01
Phibro Animal Health Corporation (PAHC) declares $0.12/share quarterly dividend, in line with previous. Forward yield 2.86% Payable June 26; for shareholders of record June 5; ex-div June 5. More on e...
05-08 04:53